OGEN
ORAGENICS INC
Next earnings Aug 6, 2026
$0.59
▲ +2.55%$0.59▼ -83.51%
over 1Y
L $0.50EODHDH $4.05
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+2.6%
1W+1.6%
1M-0.5%
3M+10.8%
YTD-30.1%
1Y-83.5%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 7 analysts
Buy
Conservative balance sheet (liabilities/equity 0.22x); but revenue fell -71.4% YoY.
Revenue (FY2023) $37.7K · FY2023
ORAGENICS INC shows $37.7K in FY2023 revenue (-71.4% YoY), a -26140.0% net margin, and -118.9% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $87.0K | $132K | $37.7K | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$15.8M | -$14.4M | -$20.9M | -$10.6M | -$9.36M |
| Net income | -$15.7M | -$14.3M | -$20.7M | -$10.6M | -$9.84M |
| Diluted EPS | — | -$7.11 | -$9.18 | -$47.88 | -$4.56 |
| Net margin | -18062.0% | -10864.0% | -54858.1% | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value-$1.85M
EV / EBITDA—
EV / Sales-49.2
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-386.6%
FCF yield-368.2%
Quality & risk
ROIC (est.)-89.3%
Free cash flow-$9.37M
Total debt—
Net cash$4.40M
Altman Z-Score-32.74 distress
Piotroski F-Score4/8
Capital returns
Buyback yield0.1%
Dividend yield (est.)—
Shareholder yield0.1%
Shares Δ YoY-79.8%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗DEFA14AFiling2026-05-20open ↗DEF 14APeriod ending 2026-05-202026-05-20open ↗8-KPeriod ending 2026-05-182026-05-19open ↗PRE 14APeriod ending 2026-05-082026-05-08open ↗10-QPeriod ending 2026-03-312026-05-08open ↗8-KPeriod ending 2026-05-072026-05-07open ↗8-KPeriod ending 2026-04-132026-04-13open ↗8-KPeriod ending 2026-03-272026-03-31open ↗EFFECTFiling2026-03-20open ↗CORRESPFiling2026-03-19open ↗S-3/AFiling2026-03-19open ↗10-KPeriod ending 2025-12-312026-03-16open ↗
Frequently asked
- Is ORAGENICS INC (OGEN) a buy?
- OGEN currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.22x); but revenue fell -71.4% YoY.
- What is ORAGENICS INC's quality score?
- OGEN scores 37.11764705882352/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001174940, latest 10-Q filed 2026-05-08) · EODHD · as of 6/26/2026, 1:14:37 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.